- Home
- AFCG vs ABVC Comparison
AFCG vs ABVC Comparison
Compare AFCG & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AFCG | ABVC |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.9M | 50.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | AFCG | ABVC |
|---|---|---|
| Price | $2.24 | $1.66 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.75 | N/A |
| AVG Volume (30 Days) | ★ 247.7K | 56.7K |
| Earning Date | 03-04-2026 | 11-03-2025 |
| Dividend Yield | ★ 27.15% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $797,916.00 |
| Revenue This Year | N/A | $735.18 |
| Revenue Next Year | $2.19 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 56.52 |
| 52 Week Low | $2.06 | $0.40 |
| 52 Week High | $8.88 | $5.48 |
Technical Indicators
Market Signals| Indicator | AFCG | ABVC |
|---|---|---|
| Relative Strength Index (RSI) | 38.63 | 32.72 |
| Support Level | $2.20 | $1.53 |
| Resistance Level | $2.38 | $1.74 |
| Average True Range (ATR) | 0.11 | 0.12 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 28.85 | 22.81 |
Price Performance
Historical ComparisonAbout AFCG AFC Gamma Inc.
Advanced Flower Capital Inc is a commercial mortgage REIT that provides institutional loans to cannabis operators in the U.S. Through the management team's deep network and related credit and cannabis expertise. The company originates, structures, and underwrites loans secured by quality real estate assets, license value, and cash flows.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.